Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: Possibilities for combination therapy

Cell Proliferation

Volumn 40, Issue 5, 2007, Pages 768-779

  Banu, N ^a   Buda, A ^a   Chell, S ^b   Elder, D ^b   Moorghen, M ^a   Paraskeva, C ^b   Qualtrough, D ^b   Pignatelli, M ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL MOTILITY; COLON CANCER; COLON CARCINOMA; DRUG MECHANISM; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DNA PRIMERS; HUMANS; NITROBENZENES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TRANS-ACTIVATION (GENETICS);

EID: 34548682769     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00459.x     Document Type: Article

References (35)

1. 2. Cancer Res. 61, 81 87.
2. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR (2003) Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8, 649 654.
3. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F (1999) High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer 83, 470 475.
4. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278, 35451 35457.
5. Buda A, Qualtrough D, Jepson MA, Martines D, Paraskeva C, Pignatelli M (2003) Butyrate downregulates α2β1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines. Gut 52, 729 734.
6. Campos-Gonzalez R, Glenney JR Jr. (1991) Immunodetection of the ligand-activated receptor for epidermal growth factor. Growth Factors 4, 305 316.
7. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Int. J. Cancer 91, 894 899.
8. Crew TE, Elder DJE, Paraskeva C (2000) A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 21, 69 77.
9. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, Pignatelli M, Bodmer WF (1999) Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc. Natl Acad. Sci. USA 96, 2316 2321.
10. Elder DJ, Halton DE, Crew TE, Paraskeva C (2000) Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int. J. Cancer 86, 553 560.
11. Elder DJE, Halton DE, Hague A, Paraskeva C (1997) Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin. Cancer Res. 3, 1679 1683.
12. Elder DJ, Halton DE, Playle LC, Paraskeva C (2002) The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int. J. Cancer 99, 323 327.
13. 2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 280, 24053 24063.
14. Kirkland SC (1985) Dome formation by a human colonic adenocarcinoma cell line (HCA-7). Cancer Res. 45, 3790 3795.
15. Marsh KA, Stamp GWH, Kirkland SC (1993) Isolation and characterisation of multiple cell types from a single human colonic carcinoma: tumorigenicity of these cell types in a xenograft system. J. Pathol. 170, 441 450.
16. Mulcahy HE, O'Donoghue D (2002) Nonsteroidal anti-inflammatory drugs and their colonic effects: more interesting than irritating? Eur. J. Gastroenterol. Hepatol. 14, 1177 1178.
17. Pai R, Nakamura T, Moon WS, Tarnawski AS (2003) Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J. 17, 1640 1647.
18. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289 293.
19. Palmer DG, Paraskeva C, William AC (1997) Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occuring lumenal factors butyrate and deoxycholate. Int. J. Cancer 73, 702 706.
20. Patrik G, Hochegger K (1999) Inhibition of epidermal-growth-factor- dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J. Cancer Res. Clin. Oncol. 125, 379 388.
21. 2. Gut 35, 675 678.
22. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, Rigas B (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta 1258, 215 223.
23. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60, 293 297.
24. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122, 518 523.
25. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori M (1998) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274, G1061 G1067.
26. 2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J. Biol. Chem. 279, 14287 14293.
27. Shao J, Sheng H, Inoue H, Morrow JD, Dubois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275, 33951 33956.
28. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99, 2254 2259.
29. 2 in human colon cancer cells. Cancer Res. 58, 362 366.
30. 2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276, 18075 18081.
31. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6, 1024 1928.
32. Tsujii M, Kawano S, Dubois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94, 3336 3340.
33. Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790 804.
34. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, Dubois RN (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60, 6045 6051.
35. Zhang H, Sun XF (2002) Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am. J. Gastroenterol. 97, 1037 1041.